225 related articles for article (PubMed ID: 24568548)
1. Adenovirus vector-induced CD8⁺ T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi Infection.
Vasconcelos JR; Dominguez MR; Neves RL; Ersching J; Araújo A; Santos LI; Virgilio FS; Machado AV; Bruna-Romero O; Gazzinelli RT; Rodrigues MM
Hum Gene Ther; 2014 Apr; 25(4):350-63. PubMed ID: 24568548
[TBL] [Abstract][Full Text] [Related]
2. Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.
Rigato PO; de Alencar BC; de Vasconcelos JR; Dominguez MR; Araújo AF; Machado AV; Gazzinelli RT; Bruna-Romero O; Rodrigues MM
Infect Immun; 2011 May; 79(5):2120-30. PubMed ID: 21357719
[TBL] [Abstract][Full Text] [Related]
3. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.
de Alencar BC; Persechini PM; Haolla FA; de Oliveira G; Silverio JC; Lannes-Vieira J; Machado AV; Gazzinelli RT; Bruna-Romero O; Rodrigues MM
Infect Immun; 2009 Oct; 77(10):4383-95. PubMed ID: 19651871
[TBL] [Abstract][Full Text] [Related]
4. Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.
Barbosa RP; Filho BG; Dos Santos LI; Junior PA; Marques PE; Pereira RV; Cara DC; Bruña-Romero O; Rodrigues MM; Gazzinelli RT; Machado AV
PLoS One; 2013; 8(4):e61795. PubMed ID: 23637908
[TBL] [Abstract][Full Text] [Related]
5. Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection.
Takayama E; Ono T; Carnero E; Umemoto S; Yamaguchi Y; Kanayama A; Oguma T; Takashima Y; Tadakuma T; García-Sastre A; Miyahira Y
Int J Parasitol; 2010 Nov; 40(13):1549-61. PubMed ID: 20620143
[TBL] [Abstract][Full Text] [Related]
6. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection.
Miyahira Y; Takashima Y; Kobayashi S; Matsumoto Y; Takeuchi T; Ohyanagi-Hara M; Yoshida A; Ohwada A; Akiba H; Yagita H; Okumura K; Ogawa H
Infect Immun; 2005 Nov; 73(11):7356-65. PubMed ID: 16239534
[TBL] [Abstract][Full Text] [Related]
7. A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
PLoS Pathog; 2015 May; 11(5):e1004828. PubMed ID: 25951312
[TBL] [Abstract][Full Text] [Related]
8. Trypanosoma cruzi: protective response of vaccinated mice is mediated by CD8+ cells, prevents signs of polyclonal T lymphocyte activation, and allows restoration of a resting immune state after challenge.
Paiva CN; Castelo-Branco MT; Lannes-Vieira J; Gattass CR
Exp Parasitol; 1999 Jan; 91(1):7-19. PubMed ID: 9920038
[TBL] [Abstract][Full Text] [Related]
9. Experimental Nanovaccine Offers Protection Against Repeat Exposures to
Chowdhury IH; Lokugamage N; Garg NJ
Front Immunol; 2020; 11():595039. PubMed ID: 33414785
[TBL] [Abstract][Full Text] [Related]
10. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191
[TBL] [Abstract][Full Text] [Related]
11. Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine.
Vasconcelos JR; Bruña-Romero O; Araújo AF; Dominguez MR; Ersching J; de Alencar BC; Machado AV; Gazzinelli RT; Bortoluci KR; Amarante-Mendes GP; Lopes MF; Rodrigues MM
PLoS Pathog; 2012; 8(5):e1002699. PubMed ID: 22615561
[TBL] [Abstract][Full Text] [Related]
12. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.
Pereira IR; Vilar-Pereira G; Marques V; da Silva AA; Caetano B; Moreira OC; Machado AV; Bruna-Romero O; Rodrigues MM; Gazzinelli RT; Lannes-Vieira J
PLoS Pathog; 2015 Jan; 11(1):e1004594. PubMed ID: 25617628
[TBL] [Abstract][Full Text] [Related]
13. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.
Araújo AF; de Alencar BC; Vasconcelos JR; Hiyane MI; Marinho CR; Penido ML; Boscardin SB; Hoft DF; Gazzinelli RT; Rodrigues MM
Infect Immun; 2005 Sep; 73(9):6017-25. PubMed ID: 16113322
[TBL] [Abstract][Full Text] [Related]
14. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
Basso B; Marini V
Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
[TBL] [Abstract][Full Text] [Related]
15. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.
Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H
Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768
[TBL] [Abstract][Full Text] [Related]
16. Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein.
Chou B; Hisaeda H; Shen J; Duan X; Imai T; Tu L; Murata S; Tanaka K; Himeno K
Microbes Infect; 2008 Mar; 10(3):241-50. PubMed ID: 18321749
[TBL] [Abstract][Full Text] [Related]
17. Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
Cazorla SI; Frank FM; Becker PD; Corral RS; Guzmán CA; Malchiodi EL
Vaccine; 2008 Apr; 26(16):1999-2009. PubMed ID: 18342408
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
Gupta S; Garg NJ
PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
[TBL] [Abstract][Full Text] [Related]
19. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
[TBL] [Abstract][Full Text] [Related]
20. DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene.
Fujimura AE; Kinoshita SS; Pereira-Chioccola VL; Rodrigues MM
Infect Immun; 2001 Sep; 69(9):5477-86. PubMed ID: 11500420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
